ACLU Challenges Patents on Breast Cancer Genes

Publication
Article
OncologyONCOLOGY Vol 23 No 7
Volume 23
Issue 7

The American Civil Liberties Union and the Public Patent Foundation at Benjamin N. Cardozo School of Law filed a lawsuit charging that patents on two human genes associated with breast and ovarian cancer stifle research that could lead to cures and limit women’s options regarding their medical care.

The American Civil Liberties Union and the Public Patent Foundation at Benjamin N. Cardozo School of Law filed a lawsuit charging that patents on two human genes associated with breast and ovarian cancer stifle research that could lead to cures and limit women's options regarding their medical care. Mutations along the BRCA1 and BRCA2 genes are responsible for most cases of hereditary breast and ovarian cancers. The lawsuit argues that the patents on these genes are unconstitutional and invalid.

Articles in this issue
What Is the Optimal Initial Treatment of Low-Risk Papillary Thyroid Cancer (and Why Is It Controversial)?
What Is the Optimal Initial Treatment of Low-Risk Papillary Thyroid Cancer (and Why Is It Controversial)?
Low-Risk Papillary Thyroid Cancer: Treatment Options and Patient Perceptions
Can Risk-Adapted Treatment Recommendations Replace the ‘One Size Fits All’ Approach for Early-Stage Thyroid Cancer Patients?
Prophylactic Central Lymph Node Dissection: Continued Controversy
Music Therapy
Music Therapy
LHRH Antagonists vs LHRH Agonists: Which Is More Beneficial in Prostate Cancer Therapy?
Is There a Role for LHRH Antagonists in Prostate Cancer?
Important Considerations in LHRH Antagonist Therapy for Prostate Cancer
The Role of LHRH Antagonists in the Treatment of Prostate Cancer
Maintenance Therapy With Pemetrexed Improves Overall Survival in Advanced NSCLC
PARP Inhibitors Show Promise for Hard-to-Treat Breast Cancers
Therapeutic Cancer Vaccine Significantly Prolongs Disease-Free Survival for Follicular Lymphoma
Vaccine Improves Response Rate and Extends Progression-Free Survival in Metastatic Melanoma
‘Natural’ Hormone Replacement and Breast Cancer Risk: Evidence for Safety and Efficacy
Phase IIIB Trial of Intermittent Degarelix Therapy Launched
Recent Videos
Patients with node-negative disease who are older and have comorbidities may not be suitable to receive CDK4/6 inhibitors.
An observed carryover effect with CDK4/6 inhibitors may reduce the risk of recurrence years after a patient stops treatment.
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Following progression on a CDK4/6 inhibitor, ascertaining the endocrine sensitivity of HR-positive/HER2-negative disease may inform sequential treatment.
Related Content
No Breast Cancer Events Noted When Breastfeeding After ET in HR+ Disease

No Breast Cancer Events Noted When Breastfeeding After ET in HR+ Disease

Ariana Pelosci
July 20th 2025
Article

Updated POSITIVE trial findings showed no significant breast cancer events in patients who breastfed following endocrine therapy for HR+ breast cancer.

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS
April 21st 2025
Podcast

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Strategizing ADC Use to Enhance Breast Cancer Outcomes

Strategizing ADC Use to Enhance Breast Cancer Outcomes

Ariana Pelosci
July 17th 2025
Article

Paolo Tarantino, MD, PhD, discusses sequencing ADCs, managing cross-resistance, and understanding ADC composition for patients with breast cancer.

Low grade serous ovarian cancer, a rare epithelial ovarian cancer subtype, requires differentiated treatment from its high-grade counterpart.

Redefining the Treatment Paradigm in Low Grade Serous Ovarian Cancer

Kathleen N. Moore, MD, MS
March 17th 2025
Podcast

Low grade serous ovarian cancer, a rare epithelial ovarian cancer subtype, requires differentiated treatment from its high-grade counterpart.

3 Intraoperative Radiotherapy: Alive and Well in the Bronx

3 Intraoperative Radiotherapy: Alive and Well in the Bronx

Caroline Oska;Eleni Kohilakis;Jana Fox
July 15th 2025
Article
Relacorilant plus nab-paclitaxel led to a median PFS and OS of 6.54 months and 15.97 months in patients with platinum-resistant ovarian cancer.

FDA Receives sNDA for Relacorilant in Platinum-Resistant Ovarian Cancer

Tim Cortese
July 15th 2025
Article

Relacorilant plus nab-paclitaxel led to a median PFS and OS of 6.54 months and 15.97 months, respectively, in patients with platinum-resistant ovarian cancer.